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Staphylococcal infective endocarditis is a severe event requiring aggressive therapy. Antibiotic regimen depends mainly on
(1) the species of Staphylococcus fStaphylococcus aureus versus coagulase-negative staphylococci) and its resistance pat-
tern (resistance to penicillin, to methicillin, to multiple classes of antibiotics); (2) the type of infected valve (native versus
prosthetic); (3) the site of infection (left side versus right side endocarditis); (4) some underlying conditions of the host, in
particular the presence or not of intravenous drug abuse. Based on in vitro susceptibility results, animal models and clinical
trials, the following regimens are currently recommended. For native valve endocarditis, penicillin G 20 million units per day
i.v. for 4—6 weeks for penicillin-susceptible strains; a penicillinase-resistant penicillin (oxacillin) 2 gi.v. q 4 hfor 4-6 weeks
plus an aminoglycoside (gentamicin) 1 -0 mg. kg~' Lv. q 8 h for 1 week, for penicillin-resistant, methicillin-susceptible strains;
for methicillin resistant strains, vancomycin 30mg.kg.day~1 Lv. in 2—4 doses for 4—6 weeks with the addition or not of
rif ampin 600-900 mg.day~' orally. For a prosthetic valve endocarditis, a three-drug regimen (oxacillin or vancomycin, plus
gentamicin and rif ampin) and a longer duration (6 weeks or more) are generally recommended. Shorter (2 weeks) treatment
could be delivered to uncomplicated cases of right-sided endocarditis. In view of an increased resistance to classic drugs and
suboptimal efficacy of some of them, new therapeutic modalities should be looked at, in particular for endocarditis cases due
to methicillin-resistant strains.
Introduction
Among the causative agents of infective endocarditis,
staphylococci play an important and varied role.
Quantitatively, they rank second only to streptococci in
many series. Their presentation, clinical course, therapeu-
tic requirements and prognosis vary widely in relation to
the type of Staphylococcus, the site and type of the valve
infected and other host factors. On the whole, staphylococ-
cal infective endocarditis is a severe disease requiring a
precise diagnosis and an aggressive therapeutic approach.
Despite this, mortality remains substantial in some cate-
gories and an associated surgical treatment is quite often
required.
The bacteria
Staphylococci are divided into two main groups: coagu-
lase-positive staphylococci called Staphylococcus aureus,
and coagulase-negative staphylococci (CNS), comprising
more than 15 species found in man, with S. epidermidis
being the predominant one.
Regarding their sensitivity to antibiotics, the staphylo-
cocci can be divided into three categories:
(i) staphylococci susceptible to all /J-lactam agents, also
called penicillin-susceptible or ^-lactamase-negative
staphylococci. They are a minority today and represent
5-20% of all 5!. aureus and of all coagulase-negative staphy-
lococci.
(ii) staphylococci resistant to penicillin (and to the
aminopenicillins and ureidopenicillins), but susceptible to
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methicillin (and to various degrees to cephalosporins).
These staphylococci are called j3-lactamase-positive
staphylococci. They represent the majority of the staphylo-
cocci in many countries and institutions, in particular,
where the number of methicillin-resistant strains is low.
(iii) staphylococci resistant to penicillin (/J-lactamase
positive) and to methicillin due to the presence of an
altered penicillin-binding protein (called PBP2a) in the
cell wall, with a low affinity for the /J-lactam antibiotics.
Though they often appear susceptible in vitro to various
/Mactam agents, these methicillin-resistant (MR) staphylo-
cocci are considered universally resistant to all /J-lactam
antibiotics.
It should be cautioned that the in vitro demonstration of
methicillin resistance is sometimes difficult, particularly for
S. epidermidis and other CNS, and that most of the rapid
automated instruments for antibiotic susceptibility testing
often fail to detect this resistance.
The incidence of methicillin resistance in staphylococcal
strains varies widely from institution to institution (from
1-2% to more than 50%) and local data will condition the
initial empiric antibiotic regimen for staphylococcal infec-
tions.
Methicillin-resistant staphylococci are usually also resis-
tant to other families of antibiotics such as the aminogly-
cosides, the macrolides and the quinolones. Antibiotic
regimens other than vancomycin should, therefore, only be
based on in vitro susceptibility testing.
Vancomycin constitutes a unique exception, in that no
clinical S. aureus strain resistant to this glycopeptide has so
far been described. However, resistance to vancomycin is
to be expected in the future, because the transfer of such
resistance has occurred in vitro between enterococci and
staphylococci.
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The host
With staphylococcal endocarditis, perhaps more so than
with any other aetiology, two important and related host
factors exist: the site(s) of the infected valve(s) and the
type of patient (whether intravenous drug abuser (IVDA)
or not).
Usually, FVDAs present a right-sided 51 aureus endo-
carditis, which is a less severe disease, allowing a shorter
therapeutic regimen, at least for as long as there are no
lesions on the left side and no complications such as
metastatic emboli.
Non-IVDA patients most often present left-sided S.
aureus endocarditis and require a full course (4-6 weeks)
of parenteral administration of a combination of two or
more bactericidal drugs to which the isolate is susceptible.
Another very important factor lies in the type of the
valve involved, i.e. native versus prosthetic valve. Infection
of prosthetic material is probably more difficult to cure and
three antibiotics are often recommended in this situation.
Recommended antibiotic regimens
Recommended treatment regimens for staphylococcal
endocarditis are based on in vitro data, on results obtained
in animal models and occasionally on deductions from
prospective randomized comparative trials in man[1~2'.
They vary from country to country according to antibiotic
policies and drug availability or preference. It is beyond the
scope of this article to review all the data leading to
recommendations of antibiotherapy. Current regimens
will be given for each particular situation and emphasis will
be put on the related problems or possible new treatment
modalities and developments.
NATIVE VALVE (TABLE 1)
Left-sided S. aureus endocarditis
Infections due to a penicillin-susceptible strain (a rare
event) can be treated with penicillin G 16-20 million units
per day i.v. in four to six divided doses for 4-6 weeks. There
are no clinical studies comparing this regimen to alterna-
tive regimens.
Infections due to a penicillin-resistant but methicillin-
susceptible strain (representing the majority of cases in
many institutions) requires the parenteral administration
of a penicillinase-resistant semi-synthetic penicillin such
as oxacillin, flucloxacillin (Europe) or nafcillin (U.S.A.)
associated or not with an aminoglycoside (generally
gentamicin or tobramycin).
The usual dosage for the /}-lactam is 2 g q 4 h i.v. for 4—6
weeks. The dosage for the aminoglycoside (gentamicin or
tobramycin) is 10 mg.kg"1 q 8 h i.v. for 3-5 days.
The only prospective comparative study available
showed that 2 weeks of gentamicin associated with nafcillin
versus nafcillin alone decreased the duration of bacter-
aemia (2-8 versus 11 days), but increased the level of renal
toxicity. No difference in mortality was observed131.
Infections caused by a methicillin-resistant strain are
treated at the present time with vancomycin, associated
with or without other agents such as rifampin and/or
aminoglycosides, when they are active on the strain.
Vancomycin should be given i.v. at a dosage of
30 mg.kg.day~1 in two to four equally divided doses for 6
weeks and adjusted to the renal function. Optimal peak
and trough serum levels should be 25-30 /ig.ml"1 and
10 /ig.ml"', respectively (in the q 12 h regimen). The
proposition to add rifampin (600-900 /ig.day"1 orally for 6
weeks) is based on its excellent intra- and extracellular bac-
tericidal activity on staphylococci. However, resistance to
rifampin can occur, even when combined to vancomycin.
For this reason also, a third drug such as gentamicin (only
when the organism is susceptible) could be added for the
first 2 weeks (gentamicin 10 mg.kg"1 q 8 h per day i.v.).
There are no prospective clinical trials to back these rec-
ommendations; they are based on in vitro data and the
results of animal studies demonstrating an increased
efficacy of a three-drug regimen141.





















2 g q 4 h i.v.
1-0 mg.kg"' q 8 h i.v.
1 g q 12 h i.v.
600 mg.day"1 orally
10 mg-kg"1 q 8 h i.v.
1-5 g q 4 h i.v.
10 mg.kg"' q 8 h
1 g q 12 h i.v.
600 mg.day"1 orally











Methicillin-susceptible As for i aureus
Methicillin-resistant As for S. aureus
Ciprofloxacin 300 mg q 12 h i.v. for 1 week
then 750 mg q 12 h orally for 3 weeks
rifampin 300 mg q 12 h orally for 3 weeks
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Right sided S. aureus endocarditis
Infections due to a methicillin-susceptible strain can be
treated by a 2-week course of a semi-synthetic penicilli-
nase-resistant penicillin (PRP) such as nafcillin 1-5 g q 4 h
i.v., associated or not with an aminoglycoside (usually gen-
tamicin or tobramycin 1-0 mg.kg"1 q 8 h i.v.151.
Infections due to a methicillin-resistant strain should be
treated with vancomycin 1 g q 12 h i.v. for 4 weeks, associ-
ated with or without rifampin 600 mg.day"1 orally for 4
weeks'61.
Coagulase-negative staphylococci endocarditis
Treatment regimens for staphylococcal endocarditis due
to a coagulase-negative strain do not differ from those for
S. aureus, as long as the strain is susceptible to the classical
agents. No prospective study has yet been conducted with
this rather unusual organism in the setting of native valve
endocarditis, but a retrospective analysis of 35 cases sug-
gests a better efficacy of combination therapy*71.
PROSTHETIC VALVE (TABLE 2)
Staphylococcus aureus infection
This very serious form of S. aureus endocarditis is usually
treated with an aminoglycoside (for 2 weeks), combined
either to a PRP (such as oxacillin) if the strain is susceptible
to PRPs, or to vancomycin, if the strain is resistant to
PRPs. Some experts advocate the addition of rifampin.
Coagulase-negative staphylococci infection
The treatment of this rather frequent condition relies
mostly on the susceptibility pattern of the causative organ-
ism. Early infections (defined as those occurring less than
1 year after surgery) tend to be due to multiresistant
organisms acquired during the hospital stay, whereas late
infections are more often caused by more susceptible com-
munity-acquired organisms. In the former situation, van-
comycin is often combined with both gentamicin and
rifampin, a regimen more effective than vancomycin
alone'8'.
Two antibiotics (vancomycin + rifampin for 6 weeks in
methicillin-resistant cases) or three (with the addition of
gentamicin for 2 weeks) were not found to be different in
terms of cure rates, but the addition of the aminoglycoside
prevented the emergence of resistance to rifampin'91.
SPECIAL SITUATIONS
Allergy to P-lactam agents
In cases of severe reaction (immediate-type hypersensi-
tivity), patients should be treated with vancomycin. In less
severe cases, a cephalosporin (such as cephalothin or cefa-
zolin) could be considered if the strain is not resistant to
methicillin. However, not all cephalosporins are equivalent
to PRP and not all are suitable for treating severe staphy-
lococcal infections.
Because vancomycin could well be less efficacious than
PRPs'6-101, a history of allergy to ^-lactams should be care-
fully documented before renouncing a /J-lactam agent.
Short regimens
Right-sided S. aureus endocarditis in the IVDA could be
cured by a shorter antibiotic regimen than that usually pre-
scribed for the other presentations of staphylococcal endo-
carditis. This is important in view of the low compliance
reported in this population. As already mentioned, 2 weeks
of i.v. nafcillin 1-5 g q 4 h associated with tobramycin
1 mg.kg-1 q 8 h gave a cure rate of 94%'51.
Another short i.v. regimen combines ciprofloxacin
300 mg q 12 h i.v. for 1 week followed by 750 mg q 12 h
orally for three further weeks, with rifampin 300 mg q 12 h
orally. This was successfully given to ten patients with right-
sided S. aureus endocarditis'11'. Ciprofloxacin and related
quinolones, however, are increasingly reported as being
inactive on staphylococci.
Alternative treatments to vancomycin
Because vancomycin could not be the optimal treatment
(slow killing, toxicity, delayed efficacy, fear for future resis-
tant organisms), alternative regimens have been and
should be considered. Trimethoprim-sulphamethoxazole
could be effective for right-sided endocarditis'121.
Teicoplanin, an antibiotic related to vancomycin, could
also be used if a high dose (12-24 mg.kg.day~1) therapy
proves equivalent to, or better than, vancomycin.
Future modalities
Outpatient treatment for uncomplicated cases of endo-
carditis, either for the entire course of antibiotherapy or
after medical stabilization, has been proved a success espe-
cially for penicillin-susceptible streptococci. For staphylo-
cocci, in low-risk patients without complications (heart
failure, peripheral emboli) discharge to home after medical
stabilization could well be considered, in particular, for
patients requiring long-term therapy.
NEW DRUG REGIMENS
The association of /J-lactamase inhibitors with various )3-
lactam agents (especially penicillins), has been shown to be
active in vitro not only against methicillin-susceptible
S. aureus strains (MIC90: 1 /ig.ml"1), but also to a lesser






As for native valve
As for native valve
Vancomycin 1 g q 12 h i.v. X 6 weeks
+ rifampin 600 mg.day orally x 6 weeks
+ gentamicin 1-0 mg.kg"1 q 8 h i.v. x 2 weeks
Medical treatment of staphylococcal infective endocarditis 83
degree against methicillin-resistant strains (
8-16/jg.ml"1'13'. Several groups have demonstrated an in
vivo efficacy of this combination in experimental endo-
carditis equal to or greater than that of vancomycin113"161.
In particular, /Mactamase-negative methicillin-resistant
S. aureus strains are highly sensitive to /}-lactam agents
such as penicillin or amoxicillin, due to their affinity being
higher than that of oxacillin for the penicillin-binding pro-
tein PBP 2a. We do not claim, at the present time, that the
available associations should be used to treat severe infec-
tions and endocarditis due to methicillin-resistant S. aureus
strains, but rather that /J-lactam agents with a high affinity
for PBP 2a should be looked at, in order to replace the
classic treatment regimen when strains of staphylococci
resistant to vancomycin eventually occur.
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